A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Metabolomics in ADPKD: how plasma metabolites and lipids are associated with kidney function and kidney volume in hypertensive patients
Meta-analysis demonstrates that GFR slope might be a viable surrogate endpoint in clinical trials for CKD
Check out the agenda for this year’s Baltimore PKD Symposium on September 23, 2019.
Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)
An ADPKD Patient’s View on Screening for Intracranial Aneurysms
The PKD Foundation collaborates with ASN to support the latest Jared J. Grantham Research Fellowship recipient Ken Sutha MD, PhD
New drug compound could tackle major life-limiting kidney disease
Molecular structure of the PKD protein complex finally solved
Developing a Research Mentorship Program: The American Society of Pediatric Nephrology's Experience
Urinary T cells may be a novel candidate marker of disease activity in ADPKD
Researchers have developed a new class of drugs to tackle a common hereditary kidney disease
Using the suPAR lab test to assess total kidney volume and patients at risk for rapid progression
The ASN Foundation for Kidney Research provides more than $3 million in funding for clinical and basic research for members at all stages of their careers
For additional research information contact us!
Phone: (800) 753-2873